Contakt

Kryštof Vladimír

E-mail: vladimir.krystof@upol.cz

Publications (Impact Factor Journals)

  • [16]
    SAID, M., W. ELDEHNA, A. NOCENTINI, S. FAHIM, A. BONARDI, A. ELGAZAR, V. KRYŠTOF, D. SOLIMAN, H. ABDEL-AZIZ, P. GRATTERI, S. ABOU-SERI a C. SUPURAN. Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation. European Journal of Medicinal Chemistry. 2020, -, -. ISSN 0223-5234. IF: 4.833. PMID: 31972394
  • [15]
    JORDA, R., P. MAGAR, D. HENDRYCHOVA, K. PAUK, M. DIBUS, E. PILAROVA, A. IMRAMOVSKY a V. KRYŠTOF. Novel modified leucine and phenylalanine dipeptides modulate viability and attachment of cancer cells. European Journal of Medicinal Chemistry. 2020, -, -. ISSN 0223-5234. IF: 4.833. PMID: 31931341
  • [14]
    SALAS C., O., A. ZARATE, V. KRYŠTOF, J. MELLA, M. FAUNDEZ, J. BREA, M. LOZA, I. BRITO, D. HENDRYCHOVA, R. JORDA, A. CABRERA, R. TAPIA a C. ESPINOSA-BUSTOS. Promising 2,6,9-Trisubstituted Purine Derivatives for Anticancer Compounds: Synthesis, 3D-QSAR, and Preliminary Biological Assays. International Journal of Molecular Sciences. 2020, 21(1), pii: E161. ISSN 1422-0067. IF: 4.183. PMID: 31881717
  • [13]
    BERTRAND, J., H. DOSTÁLOVÁ, V. KRYŠTOF, R. JORDA, A. CASTRO, J. MELLA, C. ESPINOSA-BUSTOS, A. ZARATE a O. SALAS C.. nema afiliaci ÚMTM_New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia. Bioorganic Chemistry. 2020, -, -. ISSN 0045-2068. IF: 3.926. PMID: 31699386
  • [12]
    VOLLER, J., L. ZAHAJSKA, L. PLÍHALOVÁ, J. JERABKOVA, D. BURGET, A. PATAKI, V. KRYŠTOF, M. ZATLOUKAL, J. BRABEK, D. ROSEL, V. MIK, M. TKAC, T. POSPÍŠIL, T. GUCKÝ, K. DOLEZAL a M. STRNAD. 6-Substituted purines as ROCK inhibitors with anti-metastatic activity. Bioorganic Chemistry. 2019, 90, 103005. ISSN 0045-2068. IF: 3.926. PMID: 31271944
  • [11]
    KRAJČOVIČOVÁ, S., R. JORDA, D. HENDRYCHOVA, V. KRYŠTOF a M. SOURAL. Solid-phase synthesis for thalidomide-based proteolysis-targeting chimeras (PROTAC). Chemical Communications. 2019, 55(7), -. ISSN 929-932. IF: 6.290. PMID: 30601480
  • [10]
    LASÁK, P., K. MOTYKA, V. KRYŠTOF a J. STYSKALA. Synthesis, Bacteriostatic and Anticancer Activity of Novel Phenanthridines Structurally Similar to Benzo[c]phenanthridine Alkaloids. Molecules. 2018, 23(9), pii: E2155. ISSN 1420-3049. IF: 3.098. PMID: 30150591
  • [9]
    KRAJČOVIČOVÁ, S., T. GUCKÝ, D. HENDRYCHOVA, V. KRYŠTOF a M. SOURAL. A Stepwise Approach for the Synthesis of Folic Acid Conjugates with Protein Kinase Inhibitors. Journal of Organic Chemistry. 2017, 82(24), 13530-13541. ISSN 0022-3263. IF: 4.849. PMID: 29171753
  • [8]
    JORDA, R., Z. BUCKOVA, E. ŘEZNÍČKOVÁ, J. BOUCHAL a V. KRYŠTOF. Selective inhibition reveals cyclin-dependent kinase 2 as another kinase that phosphorylates the androgen receptor at serine 81. Biochimica et Biophysica Acta. 2018, 1865(2), 354-363. ISSN 0006-3002. IF: 4.521. PMID: 29157894
  • [7]
    VANDA, D., R. JORDA, B. LEMROVÁ, T. VOLNÁ, V. KRYŠTOF, C. MCMASTER a M. SOURAL. Synthesis of Novel N9‑Substituted Purine Derivatives from Polymer Supported α‑Amino Acids. ACS Combinatorial Science. 2015, 17(7), 426-432. ISSN 2156-8952. IF: 3.317. PMID: 26098936
  • [6]
    ŘEZNÍČKOVÁ, E., A. POPA, T. GUCKÝ, M. ZATLOUKAL, L. HAVLICEK, V. BAZGIER, K. BERKA, R. JORDA, I. POPA, A. NASEREDDIN, C. JAFFE, V. KRYŠTOF a M. STRNAD. 2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro. Bioorganic and Medicinal Chemistry Letters. 2015, 25(11), 2298-2301. ISSN 0960-894X. IF: 2.486. PMID: 25937014
  • [5]
    JORDA, R., L. HAVLICEK, I.W. MCNAE, M.D. WALKINSHAW, J. VOLLER, A. STURC, J. NAVRATILOVA, M. KUZMA, M. MISTRÍK, J. BÁRTEK, M. STRNAD a V. KRYŠTOF. Pyrazolo[4,3-d]pyrimidine Bioisostere of Roscovitine: Evaluation of a Novel Selective Inhibitor of Cyclin-Dependent Kinases with Antiproliferative Activity. Journal of Medicinal Chemistry. 2011, 54(8), 2980-2993. ISSN 0022-2623. IF: 5.248. PMID: 21417417
  • [4]
    PAPRSKÁŘOVÁ, M., V. KRYŠTOF, R. JORDA, P. DŽUBÁK, M. HAJDÚCH, J. WESIERSKA-GADEK a M. STRNAD. Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine. Journal of Cellular Biochemistry. 2009, 107(3), 428-437. ISSN 0730-2312. IF: 1.330. PMID: 19308936
  • [3]
    KRYŠTOF, V., P. CANKAR, I. FRYŠOVÁ, J. SLOUKA, G. KONTOPIDIS, P. DŽUBÁK, M. HAJDÚCH, J. SROVNAL, W.F. DE AZAVEDO, M. ORSÁG, M. PAPRSKÁŘOVÁ, J. ROLČÍK, A. LÁTR, P.M. FISCHER a M. STRNAD. 4-Arylazo-3,5-diamino-1H-pyrazole CDK Inhibitors: SAR Study, Crystal Structure in Complex with CDK2, Selectivity, and Cellular Effects. Journal of Medicinal Chemistry. 2006, 49(22), 6500-6509. ISSN 0022-2623. IF: 4.926. PMID: 17064068
  • [2]
    GUCKÝ, T., E. ŘEZNÍČKOVÁ, P. DŽUBÁK, M. HAJDÚCH a V. KRYŠTOF. Synthesis and anticancer activity of some 1,5-diaryl-3-(3,4,5-trihydroxyphenyl)-1H-pyrazolo[4,3-e][1,2,4]triazines. Monatshefte fur Chemie. 2010, 141(6), 709-714. ISSN 0026-9247. IF: 1.356.
  • [1]
    TRAVNICEK, Z., M. MALOŇ, M. BILER, M. HAJDÚCH, P. BROŽ, K. DOLEZAL, J. HOLUB, V. KRYŠTOF a M. STRNAD. Synthesis, characterization and biological activity of two nickel(II) complexes with 6-(2-chlorobenzylamino)purine. Transition Metal Chemistry. 2000, 25(3), 265-269. ISSN 0340-4285. IF: 0.825.